AASDL 2012: A shift to direction action in hepatitis C?
This article was originally published in Scrip
New antivirals that that allow for interferon-sparing regimens for treating hepatitis C drugs are set to dominate pharmaceutical thinking at this year’s meeting of the American Association for the Study of Liver Diseases in Boston on 9-13 November.
You may also be interested in...
The UK firm speaks about its efforts to tackle the virus as a recent spike in COVID-19 cases outside China heighten concerns.
Two late-stage trials of Austedo have missed their endpoints in the neurological disorder, meaning Teva will miss out on an additional revenue stream from the VMAT2 inhibitor.
The future for glucokinase activation is looking brighter after fresh data on vTv’s oral adjunct to insulin therapy in type 1 diabetes.